Meta-analysis: Anti-diabetic medications and the risk of hepatocellular cancer
Source: American Journal of Gastroenterology
Area: News
According to a meta-analysis published early online in the American Journal of Gastroenterology, diabetes medications have varying impacts on the risk for hepatocellular cancer (HCC).
Several pre-clinical and observational studies have suggested that conventional diabetes medications may modify the risk of HCC. To better understand these associations, researchers performed a systematic review and meta-analysis of 10 studies reporting 22,650 cases of HCC in 334,307 patients with type 2 diabetes. There were five case-control studies, three cohort studies and two randomised controlled trials (RCTs).
Studies were included if they:
(1) evaluated and clearly defined exposure to metformin, thiazolidinediones (TZDs), sulfonylureas, and/or insulin, (2) reported HCC outcomes in patients with DM, and (3) reported relative risks or odds ratio (OR) or provided data for their estimation.
Summary OR estimates with 95% confidence intervals (CIs) were estimated. ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news
More News: Cancer | Cancer & Oncology | Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Fortamet | Gastroenterology | Insulin | Metformin | Study